Screening for Vitamin D Deficiency in Adults: US Preventive Services Task Force Recommendation Statement. Krist AH, et al, JAMA 2021.
Notes sur les tags :
Réaliser des modifications :
Pour modifier ce document, il est nécessaire d'être connecté au site. Pour cela, assurez-vous d'avoir des identifiants valides. Si vous n'en avez pas,
contactez-nous. Pour vous connecter, cliquez sur l'icône
dans la barre de navigation.
Résumé et points clés
Importance: Vitamin D is a fat-soluble vitamin that performs an important role in calcium homeostasis and bone metabolism and also affects many other cellular regulatory functions outside the skeletal system. Vitamin D requirements may vary by individual; thus, no one serum vitamin D level cutpoint defines deficiency, and no consensus exists regarding the precise serum levels of vitamin D that represent optimal health or sufficiency.
Objective: To update its 2014 recommendation, the US Preventive Services Task Force (USPSTF) commissioned a systematic review on screening for vitamin D deficiency, including the benefits and harms of screening and early treatment.
Population: Community-dwelling, nonpregnant adults who have no signs or symptoms of vitamin D deficiency or conditions for which vitamin D treatment is recommended. EVIDENCE ASSESSMENT: The USPSTF concludes that the overall evidence on the benefits of screening for vitamin D deficiency is lacking. Therefore, the balance of benefits and harms of screening for vitamin D deficiency in asymptomatic adults cannot be determined. RECOMMENDATION: The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for vitamin D deficiency in asymptomatic adults. (I statement).
Références de l'article
- Screening for Vitamin D Deficiency in Adults: US Preventive Services Task Force Recommendation Statement.
- Screening for Vitamin D Deficiency in Adults: US Preventive Services Task Force Recommendation Statement.
- Krist AH, Davidson KW, Mangione CM, Cabana M, Caughey AB, Davis EM, Donahue KE, Doubeni CA, Epling JWJ, Kubik M, Li L, Ogedegbe G, Owens DK, Pbert L, Silverstein M, Stevermer J, Tseng C, Wong JB, US Preventive Services Task Force
- JAMA
- 2021
- JAMA. 2021 Apr 13;325(14):1436-1442. doi: 10.1001/jama.2021.3069.
- Adult, Asymptomatic Diseases, Humans, *Mass Screening/adverse effects/methods, Vitamin D/*analogs & derivatives/blood/therapeutic use, Vitamin D Deficiency/blood/*diagnosis/drug therapy, Vitamins/therapeutic use
- Recommandations, Nutrition, sd, VitamineD, USPSTF, USA
- Liens
- Traduction automatique en Français sur Google Translate
- DOI: 10.1001/jama.2021.3069
- PMID: 33847711
- Articles similaires
- Cité par
- Références
- Twitter
- Twitter cet article (lien vers l'article)
- Twitter cet article (lien vers cette page)
Éditer la discussion
Références